10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

HSD17B14 antibody - middle region

Rabbit Polyclonal Antibody
Catalog # AI14020

Product Information

Application	WB
Primary Accession	Q9BPX1
Other Accession	NM_016246, NP_057330
Reactivity	Human
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	28317

Additional Information

Gene ID	51171
Alias Symbol	DHRS10, retSDR3, SDR47C1
Other Names	17-beta-hydroxysteroid dehydrogenase 14, 17-beta-HSD 14, 1.1.1.-, 17-beta-hydroxysteroid dehydrogenase DHRS10, Dehydrogenase/reductase SDR family member 10, Retinal short-chain dehydrogenase/reductase retSDR3, HSD17B14, DHRS10, SDR3
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-HSD17B14 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	HSD17B14 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	HSD17B14 (HGNC:23238)
Function	Catalyzes the NAD(+)-dependent oxidation of L-fucose, yielding L-fucono-1,5-lactone, which rapidly converts spontaneously to L-fucone-1,4-lactone. Can also act on D-arabinose and L-galactose, with lower catalytic efficiency (PubMed:38944119). Does not use NADPH (PubMed:38944119). May be the initial enzyme of the L-fucose degradation pathway in mammals (PubMed:17067289, PubMed:38944119).
Cellular Location	Cytoplasm.

Tissue Location	Highly expressed in brain, placenta, liver and kidney.

References

Haeseleer F.,et al.Methods Enzymol. 316:372-383(2000).
Clark H.F.,et al.Genome Res. 13:2265-2270(2003).
Lukacik P.,et al.Biochem. J. 402:419-427(2007).

Images



WB Suggested Anti-HSD17B14 Antibody Titration: 0.2-1 µg/ml
ELISA Titer: 1:1562500
Positive Control: Human Liver

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.